Last updated on February 2018

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease


Brief description of study

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.

Clinical Study Identifier: NCT02544204

Contact Investigators or Research Sites near you

Start Over

Craig Walker, MD

Cardiovascular Institute of the South
Houma, LA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.